REDMOND, Wash.--(BUSINESS WIRE)--Micronics, Inc., a leading developer of point-of-care molecular and immunohematology diagnostic products, announced today that it has entered into a license agreement with PHRI Properties, Inc., a nonprofit corporation wholly owned by the University of Medicine & Dentistry of New Jersey, for the right to make, have made, use and sell Micronics’ products that incorporate PHRI’s molecular beacons technology.
Micronics is advancing a family of near-patient, point-of-care molecular tests for infectious disease diagnosis and forensic testing. These tests employ Micronics’ microfluidics technologies, which enable substantial reductions in both the volume of a sample taken from a patient and the amount of reagents required to perform a nucleic acid amplification assay for the detection of the unique genes present in infectious disease pathogens. Molecular beacons are highly specific probes that fluoresce in a characteristic color if a target gene is present in a patient’s sample. These probes are incorporated into Micronics’ microfluidics cartridges for ease of use and prolonged storage at room temperature. The cartridges can perform either single or multiplex pathogen detection. Each cartridge is processed by a lightweight, low-cost, battery-powered instrument with enabled software connectivity. Micronics’ tests are designed to provide a result in under thirty minutes, directly from sample acquisition in a sealed disposable cartridge.
About Micronics
Micronics is a privately held company located in Redmond, Washington that is advancing a unique portfolio of point-of-care molecular diagnostic products for infectious disease detection, diagnosis and treatment monitoring. The Company has developed a significant patent estate in microfluidics and related technologies that enable the processing of biological and environmental samples directly in disposable devices, and the performance of highly accurate and affordable tests in a fraction of the time required by most molecular diagnostic tests in use today. The Company also provides custom product development on behalf of partners and clients worldwide. For additional information, please visit www.micronics.net.
About PHRI Properties, Inc.
Molecular beacons technology was developed at The Public Health Research Institute (PHRI), which began as an independent, not-for-profit research organization, founded in 1941 in New York City. In 2002, PHRI moved to the International Center for Public Health at the University of Medicine & Dentistry of New Jersey (UMDNJ), bringing together under one roof PHRI, the Department of Microbiology and Molecular Genetics of the New Jersey Medical School, and the Global Tuberculosis Institute. In December 2006, PHRI was officially incorporated into the New Jersey Medical School, and molecular beacons technology was assigned to PHRI Properties, Inc. For additional information, please visit www.molecular-beacons.org.
Contact:
Micronics President/CEO Karen Hedine, 425-895-9197 x 126 khedine@micronics.net
